A61K 39/0005
Vertebrate antigens
Official title: {Vertebrate antigens (from snakes A61K39/38)}
A61K39/0005 (Vertebrate antigens) appears on 6,117 US grants and 11,056 published applications in this corpus.
Search patents in A61K- Granted patents
- 6,117
- Published applications
- 11,056
- Assignees
- 2,966
- Inventors
- 13,299
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 0 | 0 |
| 1978 | 3 | 0 |
| 1979 | 6 | 0 |
| 1980 | 6 | 0 |
| 1981 | 8 | 0 |
| 1982 | 8 | 0 |
| 1983 | 5 | 0 |
| 1984 | 3 | 0 |
| 1985 | 4 | 0 |
| 1986 | 5 | 0 |
| 1987 | 10 | 0 |
| 1988 | 9 | 0 |
| 1989 | 13 | 0 |
| 1990 | 11 | 0 |
| 1991 | 4 | 0 |
| 1992 | 19 | 0 |
| 1993 | 28 | 0 |
| 1994 | 15 | 0 |
| 1995 | 17 | 0 |
| 1996 | 24 | 0 |
| 1997 | 41 | 0 |
| 1998 | 67 | 0 |
| 1999 | 63 | 0 |
| 2000 | 51 | 0 |
| 2001 | 70 | 27 |
| 2002 | 72 | 164 |
| 2003 | 51 | 617 |
| 2004 | 52 | 276 |
| 2005 | 50 | 243 |
| 2006 | 74 | 232 |
| 2007 | 124 | 186 |
| 2008 | 131 | 203 |
| 2009 | 102 | 266 |
| 2010 | 115 | 307 |
| 2011 | 152 | 331 |
| 2012 | 131 | 300 |
| 2013 | 181 | 323 |
| 2014 | 198 | 361 |
| 2015 | 233 | 448 |
| 2016 | 277 | 534 |
| 2017 | 308 | 560 |
| 2018 | 347 | 611 |
| 2019 | 444 | 688 |
| 2020 | 456 | 736 |
| 2021 | 431 | 745 |
| 2022 | 393 | 778 |
| 2023 | 347 | 668 |
| 2024 | 388 | 624 |
| 2025 | 345 | 487 |
| 2026 | 222 | 341 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Lipid nanoparticles comprising sterols and mRNA6 Oct 2026US 12,751,999 B2eTheRNA Immunitherapies NV
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- NKG2A-targeting antibody and use thereof6 Oct 2026US 12,753,231 B2Bioheng Therapeutics Limited
- FOXM1-derived peptide, and vaccine including same29 Sep 2026US 12,747,265 B2Oncotherapy Science, Inc.
- Selection of cancer mutations for generation of a personalized cancer vaccine29 Sep 2026US 12,749,556 B2Nouscom AG
- Modular multiplatform system for mrna drug production8 Oct 2026US 2026/0306407 A1BioNTech SE
- Antigen-specific physiologic dendritic cells for therapy8 Oct 2026US 2026/0306597 A1Emory University
- Preparation of tolerizing nanoparticles for the treatment of primary biliary cholangitis8 Oct 2026US 2026/0306598 A1Cour Pharmaceuticals Development Company, Inc.
- Timp3-derived teipp neoantigens and uses thereof8 Oct 2026US 2026/0306599 A1
- Sarcoma cancer vaccines and uses thereof8 Oct 2026US 2026/0306600 A1
Most cited
By later US patents
- Method of producing human monoclonal antibodies and kit therefor407US 5,567,610 ABioinvent International AB · 1996
- Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines290US 6,218,371 B1University of Iowa Research Foundation · 2001
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy258US 8,034,334 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- Immunotherapy against several tumors, such as lung cancer, including NSCLC198US 10,071,148 B2Immatics Biotechnologies GmbH · 2018
- Application of mRNA for use as a therapeutic agent for tumorous diseases194US 8,217,016 B2CureVac AG · 2012